These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

99 related articles for article (PubMed ID: 27931070)

  • 1. [Not Available].
    Löser P; Mross B; Lapp H; Bauer JU
    Pneumologie; 2016 Dec; 70(12):826-830. PubMed ID: 27931070
    [No Abstract]   [Full Text] [Related]  

  • 2. Alectinib surpasses crizotinib for untreated ALK-positive NSCLC.
    Gilbert JA
    Lancet Oncol; 2017 Jul; 18(7):e377. PubMed ID: 28625556
    [No Abstract]   [Full Text] [Related]  

  • 3. Crizotinib-induced cardiotoxicity: the importance of a proactive monitoring and management.
    Tartarone A; Gallucci G; Lazzari C; Lerose R; Lombardi L; Aieta M
    Future Oncol; 2015; 11(14):2043-8. PubMed ID: 26198834
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Esophageal Ulcer in a Lung Cancer Patient. Crizotinib-induced Esophageal Injury.
    Sawada T; Maeno K; Joh T
    Gastroenterology; 2015 Aug; 149(2):e6-7. PubMed ID: 26123560
    [No Abstract]   [Full Text] [Related]  

  • 5. [Crizotinib: At last in first-line treatment of advanced-stage ALK-rearranged non-small cell lung cancer].
    Giroux Leprieur E; Wislez M
    Bull Cancer; 2016 Feb; 103(2):125-6. PubMed ID: 26822904
    [No Abstract]   [Full Text] [Related]  

  • 6. Crizotinib-induced esophageal ulceration: a novel adverse event of crizotinib.
    Park J; Yoshida K; Kondo C; Shimizu J; Horio Y; Hijioka S; Hida T
    Lung Cancer; 2013 Sep; 81(3):495-496. PubMed ID: 23891512
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Crizotinib for the treatment of patients with advanced non-small cell lung cancer.
    Bowles DW; Weickhardt AJ; Doebele RC; Camidge DR; Jimeno A
    Drugs Today (Barc); 2012 Apr; 48(4):271-82. PubMed ID: 22536569
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Crizotinib as a personalized alternative for targeted anaplastic lymphoma kinase rearrangement in previously treated patients with non-small-cell lung cancer.
    Guo L; Zhang H; Shao W; Chen B
    Drug Des Devel Ther; 2015; 9():5491-7. PubMed ID: 26491259
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Successful treatment with ceritinib after crizotinib induced hepatitis.
    Sassier M; Mennecier B; Gschwend A; Rein M; Coquerel A; Humbert X; Alexandre J; Fedrizzi S; Gervais R
    Lung Cancer; 2016 May; 95():15-6. PubMed ID: 27040846
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Crizotinib: a new treatment option for ALK-positive non-small cell lung cancer.
    O'Bryant CL; Wenger SD; Kim M; Thompson LA
    Ann Pharmacother; 2013 Feb; 47(2):189-97. PubMed ID: 23386065
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Asymptomatic profound sinus bradycardia (heart rate ≤45) in non-small cell lung cancer patients treated with crizotinib.
    Ou SH; Azada M; Dy J; Stiber JA
    J Thorac Oncol; 2011 Dec; 6(12):2135-7. PubMed ID: 22088989
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Esophagitis: a novel adverse event of crizotinib in a patient with ALK-positive non-small-cell lung cancer.
    Srivastava N; VanderLaan PA; Kelly CP; Costa DB
    J Thorac Oncol; 2013 Mar; 8(3):e23-4. PubMed ID: 23407563
    [No Abstract]   [Full Text] [Related]  

  • 13. Successful treatment with alectinib after crizotinib-induced esophageal ulceration.
    Yoneshima Y; Okamoto I; Takano T; Enokizu A; Iwama E; Harada T; Takayama K; Nakanishi Y
    Lung Cancer; 2015 Jun; 88(3):349-51. PubMed ID: 25837798
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Crizotinib, a small-molecule dual inhibitor of the c-Met and ALK receptor tyrosine kinases.
    Rodig SJ; Shapiro GI
    Curr Opin Investig Drugs; 2010 Dec; 11(12):1477-90. PubMed ID: 21154129
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Crizotinib-induced fatal fulminant liver failure.
    van Geel RM; Hendrikx JJ; Vahl JE; van Leerdam ME; van den Broek D; Huitema AD; Beijnen JH; Schellens JH; Burgers SA
    Lung Cancer; 2016 Mar; 93():17-9. PubMed ID: 26898609
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hope without hype: EML4-ALK inhibition for treatment of lung cancer.
    Govindan R
    Lancet Oncol; 2011 Oct; 12(11):983-4. PubMed ID: 21933750
    [No Abstract]   [Full Text] [Related]  

  • 17. Acute kidney injury following crizotinib administration for non-small-cell lung carcinoma.
    Gastaud L; Ambrosetti D; Otto J; Marquette CH; Coutts M; Hofman P; Esnault V; Favre G
    Lung Cancer; 2013 Nov; 82(2):362-4. PubMed ID: 24001942
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Successful crizotinib rechallenge after crizotinib-induced interstitial lung disease in patients with advanced non-small-cell lung cancer.
    Asai N; Yamaguchi E; Kubo A
    Clin Lung Cancer; 2014 May; 15(3):e33-5. PubMed ID: 24702855
    [No Abstract]   [Full Text] [Related]  

  • 19. Inhibitors of the anaplastic lymphoma kinase.
    Mologni L
    Expert Opin Investig Drugs; 2012 Jul; 21(7):985-94. PubMed ID: 22612599
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Remarkable tumor response to crizotinib in a 14-year-old girl with ALK-positive non-small-cell lung cancer.
    Kim SJ; Kim DW; Kim TM; Lee SH; Heo DS; Bang YJ
    J Clin Oncol; 2012 Jun; 30(16):e147-50. PubMed ID: 22508824
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.